Biosimilar drugs in Mexico: position of the Mexican College of Rheumatology, 2012.
about
Assessing the Immunogenicity of BiopharmaceuticalsClinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatologyClinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data.Controversies in Establishing Biosimilarity: Extrapolation of Indications and Global Labeling Practices.
P2860
Biosimilar drugs in Mexico: position of the Mexican College of Rheumatology, 2012.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Biosimilar drugs in Mexico: position of the Mexican College of Rheumatology, 2012.
@en
Biosimilar drugs in Mexico: position of the Mexican College of Rheumatology, 2012.
@nl
type
label
Biosimilar drugs in Mexico: position of the Mexican College of Rheumatology, 2012.
@en
Biosimilar drugs in Mexico: position of the Mexican College of Rheumatology, 2012.
@nl
prefLabel
Biosimilar drugs in Mexico: position of the Mexican College of Rheumatology, 2012.
@en
Biosimilar drugs in Mexico: position of the Mexican College of Rheumatology, 2012.
@nl
P2093
P1433
P1476
Biosimilar drugs in Mexico: position of the Mexican College of Rheumatology, 2012
@en
P2093
Alejandro Díaz Borjón
Antonio Fraga Mouret
César Alejandro Arce Salinas
Eduardo Rubén Barreira Mercado
Efraín Díaz Jouanen
Francisco Javier Flores Murrieta
Francisco José Muñoz Barradas
Gabriel Medrano Ramírez
Juan Osvaldo Talavera Piña
Leonor Adriana Barile Fabris
P304
P356
10.1016/J.REUMA.2012.11.001
P577
2013-02-08T00:00:00Z